Drugs With Tirzepatide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
This Zepbound and Mounjaro Eye Side Effect NAION Information Page provides some important evidence regarding an increased risk of non-arteritic ischemic optic neuropathy, or NAION, associated with these two tirzepatide-containing drugs.
The FDA has been investigating “potential signals” of the eye side effect NAION with Mounjaro and Zepbound — the active ingredient is tirzepatide for both medications — as well as other glucagon-like peptide-1 (GLP-1) receptor agonist drugs, collectively referred to as GLP-1 RAs. To learn more about how Zepbound and Mounjaro might be associated with the eye side effect NAION, you can read our June 2025 Drug Injury Watch blog post, “Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs”.
An August 2025 JAMA Network Open article, “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes“, provided more evidence for an increased risk of non-arteritic ischemic optic neuropathy, or NAION, with Ozempic (semaglutide) or Mounjaro (tirzepatide) in diabetes patients.
Here are some of the facts presented in that August 2025 medical article regarding the Mounjaro eye side effect NAION, specifically in diabetes patients:
- Nonarteritic anterior ischemic optic neuropathy (NAION) is characterized by loss of vision due to decreased blood flow to the optic nerve.
- The medical researchers compared Mounjaro (tirzepatide) with other antidiabetic medications for the associated risk of NAION in patients with type 2 diabetes who had no prior diagnosis of any eye disorder.
- Mounjaro (tirzepatide) is a newer and more potent GLP-RA to treat type 2 diabetes and obesity.
- In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that when Mounjaro (tirzepatide) was compared with other antidiabetic medications, there was an increased risk of NAION.
Besides Mounjaro, as we stated earlier, there is a second GLP-1RA drug that contains the active ingredient tirzepatide, Zepbound. That medication is used for obesity and weight loss purposes. There is some evidence that the NAION eye side effect may be associated with Zepbound, given that both drugs have the active ingredient tirzepatide.
Of course, we will continue to monitor relevant medical journals for additional studies concerning the association of NAION with Mounjaro and Zepbound. Further, we await the outcome of that FDA investigation into the eye side effect NAION with Mounjaro and Zepbound.
Free Case Evaluation for Zepbound or Mounjaro Eye Side Effect NAION
We encourage you to submit a Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Zepbound or Mounjaro drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Articles About Zepbound and Mounjaro Eye Side Effect NAION With Vision Loss
NAION With Ozempic, Wegovy, Mounjaro, or Zepbound Use: Why Are There Still No Warnings?
Numerous medical studies have been published in the past couple of years about non-arteritic anterior ischemic optic neuropathy (NAION) with Ozempic, Wegovy, Mounjaro, or Zepbound use resulting in sudden vision loss.
Despite this drug safety information, the current Prescribing Information documents or drug labels in the US for these four increasingly popular drugs still do not have any warnings for doctors or patients about NAION and vision loss as of October 2026.
To read more of this article, click below:
Before we point out two recent medical news articles relevant to NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use, and whether their respective drug labels should have NAION and vision loss warnings, here are a couple of earlier pieces we wrote about those issues:
NAION Linked To Zepbound, Mounjaro, Ozempic, Wegovy: 2026 News Update (5/22/26)
Ozempic Eye Side Effect NAION Warnings Update July 2026 (7/28/26)
Now for the two recent medical news articles about NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use, as well as the present lack of any NAION and vision loss warnings here in the US:
- “GLP-1s may be linked to vision loss, but overall risk ‘very, very low’“, published online October 2, 2026, by Healio Primary Care Optometry News; and
- “GLP-1s and NAION: Do Patients Need a Warning?“, published online October 2, 2026, by Medscape Medical News.
From talking to numerous people who have vision loss due to NAION diagnosed while using Ozempic and Wegovy (which are both semaglutide-containing drugs), as well as Mounjaro and Zepbound (which are both tirzepatide-containing drugs), we can tell you that many of these people said they were disappointed there were no NAION and vision loss warnings. Moreover, some of those people were understandably angry about this failure by the responsible drug companies.
We have been investigating drug injury lawsuits against those drug companies for patients who have vision loss due to NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use.
If you have been diagnosed with NAION due to Ozempic, Wegovy, Mounjaro, or Zepbound use, you may want to submit a Case Evaluation Form online to get a free review of your potential NAION lawsuit:
Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
If you would prefer to discuss your potential NAION lawsuit with drug injury lawyer Tom Lamb, send him an email at TJL@LambLawOffice.com or call 910-256-2971.
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Mounjaro and Zepbound:
- Mounjaro, Ozempic Vision Loss Lawsuits Filings Increase – 2026 News Reports
- NAION Cases Filed in Courts for Vision Loss Legal Compensation
- NAION Linked To Zepbound Mounjaro, Ozempic, Wegovy: 2026 News Update
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- NAION With Tirzepatide-containing Drugs Mounjaro and Zepbound